CYP2C19 and clopidogrel response: More than validation in the real world

Clinical Pharmacology and Therapeutics

Volumn 91, Issue 2, 2012, Pages 170-171

  Shuldiner, A R ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; CYTOCHROME P450 2C19; MULTIDRUG RESISTANCE PROTEIN 1;

ALLELE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DRUG EFFECT; EFFECT SIZE; ELECTRONIC MEDICAL RECORD; GENETIC VARIABILITY; GENOTYPE; HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT RESPONSE; VALIDATION STUDY;

DATABASES, NUCLEIC ACID; ELECTRONIC HEALTH RECORDS; FEMALE; HUMANS; MALE; MYOCARDIAL INFARCTION; PHARMACOGENETICS; PLATELET AGGREGATION INHIBITORS; THROMBOSIS; TICLOPIDINE;

EID: 84855944274     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.324     Document Type: Review

References (10)

1. Delaney, J.T. et al. Predicting clopidogrel response using DNA samples linked to an electronic health record. Clin. Pharmacol. Ther. 91, 257-263 (2012).
2. Mega, J.L. et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 304, 1821-1830 (2010).
3. Shuldiner, A.R. et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302, 849-857 (2009).
4. Simon, T. et al. Genetic determinants of response to clopidogrel and cardiovascular events. N. Engl. J. Med. 360, 363-375 (2009).
5. Bouman, H.J. et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat. Med. 17, 110-116 (2011).
6. Sibbing, D. et al. No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting. Eur. Heart J. 32, 1605-1613 (2011).
7. Lewis, J.P. et al. Paraoxonase 1 (PON1) gene variants are not associated with clopidogrel response. Clin. Pharmacol. Ther. 90, 568-574 (2011).
8. Tatonetti, N.P. et al. Detecting drug interactions from adverse-event reports: interaction between paroxetine and pravastatin increases blood glucose levels. Clin. Pharmacol. Ther. 90, 133-142 (2011).
9. Altman, R.B. Pharmacogenomics: "noninferiority" is sufficient for initial implementation. Clin. Pharmacol. Ther. 89, 348-350 (2011).
10. Scott, S.A. et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin. Pharmacol. Ther. 90, 328-332 (2011).